241 related articles for article (PubMed ID: 20198409)
1. Drug delivery systems for intraperitoneal therapy.
Bajaj G; Yeo Y
Pharm Res; 2010 May; 27(5):735-8. PubMed ID: 20198409
[TBL] [Abstract][Full Text] [Related]
2. Development of a nanocapsule-loaded hydrogel for drug delivery for intraperitoneal administration.
Teja Surikutchi B; Obenza-Otero R; Russo E; Zelzer M; Golán Cancela I; Costoya JA; Crecente Campo J; José Alonso M; Marlow M
Int J Pharm; 2022 Jun; 622():121828. PubMed ID: 35595041
[TBL] [Abstract][Full Text] [Related]
3. Intraperitoneal drug therapy: an advantage.
Chaudhary K; Haddadin S; Nistala R; Papageorgio C
Curr Clin Pharmacol; 2010 May; 5(2):82-8. PubMed ID: 20156151
[TBL] [Abstract][Full Text] [Related]
4. Tuning the Physicochemical Characteristics of Particle-Based Carriers for Intraperitoneal Local Chemotherapy.
Alavi S; Haeri A; Mahlooji I; Dadashzadeh S
Pharm Res; 2020 Jun; 37(6):119. PubMed ID: 32494940
[TBL] [Abstract][Full Text] [Related]
5. Intraperitoneal chemotherapy for peritoneal metastases: an expert opinion.
Ceelen W; Braet H; van Ramshorst G; Willaert W; Remaut K
Expert Opin Drug Deliv; 2020 Apr; 17(4):511-522. PubMed ID: 32142389
[No Abstract] [Full Text] [Related]
6. Magnetically assisted intraperitoneal drug delivery for cancer chemotherapy.
Shamsi M; Sedaghatkish A; Dejam M; Saghafian M; Mohammadi M; Sanati-Nezhad A
Drug Deliv; 2018 Nov; 25(1):846-861. PubMed ID: 29589479
[TBL] [Abstract][Full Text] [Related]
7. Peritoneal Carcinomatosis Targeting with Tumor Homing Peptides.
Simón-Gracia L; Hunt H; Teesalu T
Molecules; 2018 May; 23(5):. PubMed ID: 29772690
[TBL] [Abstract][Full Text] [Related]
8. Pharmaceutical strategies in improving anti-tumour efficacy and safety of intraperitoneal therapy for peritoneal metastasis.
Wang P; Qu X; Che X; Luo Q; Tang X; Liu Y
Expert Opin Drug Deliv; 2021 Sep; 18(9):1193-1210. PubMed ID: 33682562
[No Abstract] [Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics.
Hasovits C; Clarke S
Clin Pharmacokinet; 2012 Apr; 51(4):203-24. PubMed ID: 22420577
[TBL] [Abstract][Full Text] [Related]
10. Nanomedicine-based intraperitoneal therapy for the treatment of peritoneal carcinomatosis - Mission possible?
Dakwar GR; Shariati M; Willaert W; Ceelen W; De Smedt SC; Remaut K
Adv Drug Deliv Rev; 2017 Jan; 108():13-24. PubMed ID: 27422808
[TBL] [Abstract][Full Text] [Related]
11. Targeting of p32 in peritoneal carcinomatosis with intraperitoneal linTT1 peptide-guided pro-apoptotic nanoparticles.
Hunt H; Simón-Gracia L; Tobi A; Kotamraju VR; Sharma S; Nigul M; Sugahara KN; Ruoslahti E; Teesalu T
J Control Release; 2017 Aug; 260():142-153. PubMed ID: 28603028
[TBL] [Abstract][Full Text] [Related]
12. Thermosensitive hydrogel system assembled by PTX-loaded copolymer nanoparticles for sustained intraperitoneal chemotherapy of peritoneal carcinomatosis.
Xu S; Fan H; Yin L; Zhang J; Dong A; Deng L; Tang H
Eur J Pharm Biopharm; 2016 Jul; 104():251-9. PubMed ID: 27185379
[TBL] [Abstract][Full Text] [Related]
13. Intraperitoneal delivery of nanoparticles for cancer gene therapy.
Hallaj-Nezhadi S; Dass CR; Lotfipour F
Future Oncol; 2013 Jan; 9(1):59-68. PubMed ID: 23252564
[TBL] [Abstract][Full Text] [Related]
14. Intraperitoneal chemotherapy against peritoneal carcinomatosis: current status and future perspective.
Kitayama J
Surg Oncol; 2014 Jun; 23(2):99-106. PubMed ID: 24721661
[TBL] [Abstract][Full Text] [Related]
15. Response to pathological processes in the peritoneal cavity--sepsis, tumours, adhesions, and ascites.
Stommel MW; Strik C; van Goor H
Semin Pediatr Surg; 2014 Dec; 23(6):331-5. PubMed ID: 25459437
[TBL] [Abstract][Full Text] [Related]
16. Optimization of drug delivery systems for intraperitoneal therapy to extend the residence time of the chemotherapeutic agent.
De Smet L; Ceelen W; Remon JP; Vervaet C
ScientificWorldJournal; 2013; 2013():720858. PubMed ID: 23589707
[TBL] [Abstract][Full Text] [Related]
17. Reduction of surgery-induced peritoneal adhesions by continuous release of streptokinase from a drug delivery system.
Yagmurlu A; Barlas M; Gursel I; Gokcora IH
Eur Surg Res; 2003; 35(1):46-9. PubMed ID: 12566787
[TBL] [Abstract][Full Text] [Related]
18. [Can dexpanthenol prevent peritoneal adhesion formation? An experimental study].
Akdeniz Y; Tarhan OR; Barut I
Ulus Travma Acil Cerrahi Derg; 2007 Apr; 13(2):94-100. PubMed ID: 17682950
[TBL] [Abstract][Full Text] [Related]
19. Genipin-crosslinked gelatin microspheres as a strategy to prevent postsurgical peritoneal adhesions: In vitro and in vivo characterization.
De Clercq K; Schelfhout C; Bracke M; De Wever O; Van Bockstal M; Ceelen W; Remon JP; Vervaet C
Biomaterials; 2016 Jul; 96():33-46. PubMed ID: 27135715
[TBL] [Abstract][Full Text] [Related]
20. Prevention of peritoneal adhesions with an in situ cross-linkable hyaluronan hydrogel delivering budesonide.
Yeo Y; Adil M; Bellas E; Astashkina A; Chaudhary N; Kohane DS
J Control Release; 2007 Jul; 120(3):178-85. PubMed ID: 17582645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
